ThromboGenics and Geymonat to collaborate on development of PlGF in angiogenesis

Irish-based biotherapeutics company ThromboGenics and Geymonat, of Catania in Italy, have entered into a collaborative agreement for the co-development of PlGF (Placental Growth Factor), a drug candidate that has shown strong potential in preclinical studies to treat conditions such as ischemic heart disease, through its distinct role in stimulating angiogenesis.

The collaboration brings into a single portfolio ThromboGenics' exclusive rights to the therapeutic applications of PlGF, and Geymonat's exclusive rights to the intellectual property, which characterises the protein sequence of PlGF.

'A number of preclinical studies have identified the therapeutic relevance of PlGF as a pro-angiogenic growth factor with important advantages over similar agents, such as VEGF,' said Professor Desire Collen, chairman and ceo of ThromboGenics. 'The goal of this alliance is to bring PlGF into the clinic, with the ultimate aim to attract a pharmaceutical partnership for later-stage clinical development and commercialisation.'

PlGF is a homologue of VEGF but interacts with receptors in a different manner. While VEGF has shown promise in the treatment of ischemic conditions, its therapeutic potential is hampered by dose-limiting side effects. PlGF, due to its more specific activity and targeted angiogenic effect, may allow for an improved risk-benefit ratio, with fewer side effects than VEGF. A variety of therapeutic applications have been identified for PlGF, including ischemic heart disease and peripheral arterial occlusive disease (PAOD), as well as bone fracture and wound healing.

Initially, the collaboration will focus on advanced preclinical and early clinical development of PlGF, including production of clinical quantities via a proprietary recombinant expression system, according to Dr Giuseppe Salvia, managing director and ceo of Geymonat.